Mini antibodies: biotech's next big thing?
Friday, September 12, 2008 - 03:42
in Biology & Nature
LONDON (Reuters) - GlaxoSmithKline Plc's head of biotech research is excited about a new generation of "slimline" antibody medicines that may be successors to current blockbusters such as Avastin and Rituxan.
Read the whole article on Reuters:Science
More from Reuters:Science
Related
- How to improve vaccines to trigger T cell as well as antibody responseThu, 3 Sep 2009, 20:51:16 EDT
- Method for fast human antibodies against flu could find broad useWed, 30 Apr 2008, 17:00:25 EDT
- Scripps research team develops new technique to tap full potential of antibody librariesThu, 15 Jan 2009, 14:32:31 EST
- Researchers rapidly turn bacteria into biotech factoriesSun, 26 Jul 2009, 16:15:29 EDT
- Stanford Alzheimer's research pinpoints antibodies that may prevent diseaseMon, 6 Jul 2009, 17:51:01 EDT